Subtype
Male Reproductive System Neoplasm
CI-CAN-00001107Explore in graph →
Non-malignant1,533 active trials27 approved drugs58 evidence items
- NCIt
- C3054
Loading cancer entity…
Subtype
CI-CAN-00001107Explore in graph →
Clinical trials
6,899 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03254420 | Evaluation of Late Toxicity Following Intensity-Modulated Radiotherapy and Two Image-Guided Strategies With Corresponding Treatment Margins.(RCMIGI) | active not recruiting | N/A | 74 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04536805 | Relapse in Previously Irradiated Prostate Bed : Stereotactic Ablative Reirradiation Potentiated by Metformin(REPAIR) | active not recruiting | Phase 1 / Phase 2 | 44 | Institut Cancerologie de l'Ouest |
| 1 |
| Jun 23, 2026 |
| clinicaltrials |
| NCT06430749 | Targeted Microwave Tissue Coagulation for Prostate Cancer(MicroPro2) | active not recruiting | N/A | 65 | Osamu UkimuraOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT02918253 | HDR Focal: Feasibility Study | active not recruiting | N/A | 60 | University Health Network, TorontoOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT04419402 | Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer(ENZA-p) | active not recruiting | Phase 2 | 162 | Australian and New Zealand Urogenital and Prostate Cancer Trials GroupOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07658573 | AI Multimodal Model for Predicting CRPC Progression Risk(AI-MM_CPRC) | active not recruiting | — | 500 | Guangxi Medical UniversityOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT06257264 | A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors | active not recruiting | Phase 1 | 103 | BeiGeneINDUSTRY | 6 | Jun 18, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT06318273 | A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 1 | 152 | AbbVieINDUSTRY | 7 | Jun 17, 2026 | clinicaltrials |
| NCT06561230 | Leveraging EA8191 to Assess AI-Augmented EHR Abstraction | active not recruiting | — | 300 | University of PennsylvaniaOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT01950351 | Hypofractionated Proton Beam Therapy for Localized Prostate Cancer | active not recruiting | Phase 2 | 241 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT05471414 | Whole-Food Plant-Based Diet to Control Weight and MetaboInflammation in Overweight/Obese Men With Prostate Cancer(WFPBD) | active not recruiting | N/A | 76 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT05683691 | Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer(VAPOR 2) | active not recruiting | N/A | 400 | Francis Medical Inc.INDUSTRY | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07597369 | Clinically Actionable Tumor-Associated Antigens in Prostate Cancer | active not recruiting | — | 1,600 | Peking University First HospitalOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07607431 | Risk Factors, Incidence, and Progression of Lymphedema Among Men With Prostate Cancer. The AWARE Cohort(AWARE) | active not recruiting | — | 214 | Rigshospitalet, DenmarkOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT00329043 | Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy | active not recruiting | Phase 2 | 64 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04240327 | Marker Driven Selection of Patients for Prostate Biopsy and Management(MDSelect) | active not recruiting | — | 289 | University of MiamiOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT03348670 | Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms(Drugs-SNPs) | active not recruiting | Phase 2 / Phase 3 | 600 | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairINDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT02537548 | Retroperitoneal Lymph Node Dissection in Treating Patients With Testicular Seminoma | active not recruiting | N/A | 55 | University of Southern CaliforniaOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT02717156 | Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors | active not recruiting | Phase 2 | 70 | University of Southern CaliforniaOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT03899987 | Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery | active not recruiting | Phase 2 | 12 | Roswell Park Cancer InstituteOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT04190446 | A Study To Evaluate Hypofractionated Proton Therapy Or IMRT For Recurrent, Oligometastatic Prostate Cancer | active not recruiting | Phase 2 | 84 | Mayo ClinicOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07126860 | The Effect of a Structured Strength and Endurance Training Program on Quality of Life, Fitness, Blood Parameters and Survival in Prostate Cancer Patients(ZMoveMent-1) | active not recruiting | N/A | 150 | Ludwig-Maximilians - University of MunichOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT04720157 | An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)(PSMAddition) | active not recruiting | Phase 3 | 1,140 | Novartis PharmaceuticalsINDUSTRY | 19 | Jun 8, 2026 | clinicaltrials |
| NCT01802346 | Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer | active not recruiting | N/A | 130 | University of Southern CaliforniaOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06891664 | Feasibility of Day-surgery Management for Patients Undergoing Robotic Radical Prostatectomy: a Randomized Trial | active not recruiting | N/A | 90 | Regina Elena Cancer InstituteOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT03445559 | A Multi-modal, Physician-centered Intervention to Improve Guideline-concordant Prostate Cancer Imaging | active not recruiting | N/A | 58 | VA Office of Research and DevelopmentFED | 1 | Jun 4, 2026 | clinicaltrials |
| NCT03725761 | Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy | active not recruiting | Phase 2 | 31 | University of Wisconsin, MadisonOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT03344211 | Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer | active not recruiting | Phase 2 | 30 | University of Southern CaliforniaOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT03873805 | PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer | active not recruiting | Phase 1 | 14 | City of Hope Medical CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05056077 | Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)(TTBF) | active not recruiting | N/A | 353 | University of California, San FranciscoOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05470699 | RefleXion PET/CT Imaging Performance in Patients With Prostate Cancer | active not recruiting | N/A | 34 | City of Hope Medical CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05477823 | Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer | active not recruiting | Early Phase 1 | 30 | University of Wisconsin, MadisonOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT03012321 | Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects | active not recruiting | Phase 2 | 70 | Northwestern UniversityOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT03600350 | pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer | active not recruiting | Phase 2 | 19 | University of Wisconsin, MadisonOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04109729 | Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer(Rad2Nivo) | active not recruiting | Phase 1 | 39 | University of UtahOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05720910 | Streamlined Geriatric and Oncological Evaluation Based On IC Technology(FRONE) | active not recruiting | N/A | 720 | Institut BergoniéOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06964412 | The Use of Artificial Intelligence Generated Contours in Radiation Planning of the Prostate Brachytherapy | active not recruiting | N/A | 36 | Brigham and Women's HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT04514484 | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | active not recruiting | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | May 28, 2026 | clinicaltrials |
| NCT06523777 | PRISM: Patient Experiences With PET Imaging in Prostate Cancer(PRISM) | active not recruiting | — | 350 | Yale UniversityOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT04070209 | Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X) | active not recruiting | Phase 2 | 66 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT05806814 | Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer(OU-SCC-EXCITE) | active not recruiting | Phase 1 | 15 | University of OklahomaOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT07608419 | Predictors of Nodal and Distant Metastatic Disease Detected by PSMA PET in Treatment-Naïve High-Risk Prostate Cancer: A Czech Multicentre Cohort Study(CZECH-PSMA) | active not recruiting | — | 400 | General University Hospital, PragueOTHER | 0 | May 27, 2026 | clinicaltrials |
| NCT02177292 | High-Dose Lymph Node Intensity Modulated Radiation Therapy and Hypofractionated Prostate (SIB)(SIB) | active not recruiting | N/A | 80 | Medical College of WisconsinOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT03582774 | Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical Prostatectomy(PSMA SRT) | active not recruiting | Phase 3 | 193 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT04263025 | AMNIOX CORD Study - Radical Prostatectomy With and Without Cryopreserved Umbilical Cord Allograft | active not recruiting | Phase 2 / Phase 3 | 100 | Hackensack Meridian HealthOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT05496959 | 177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study(LUNAR) | active not recruiting | Phase 2 | 93 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT02799706 | Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer(PEGASUS) | active not recruiting | Phase 3 | 885 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 8 | May 22, 2026 | clinicaltrials |
| NCT05682443 | ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC(PRESERVE-006) | active not recruiting | Phase 1 / Phase 2 | 148 | OncoC4, Inc.INDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT06238479 | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors(EXCEED) | active not recruiting | Phase 1 | 490 | Eli Lilly and CompanyINDUSTRY | 7 | May 22, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 23, 2026source: clinicaltrials